Cellenkos, Inc. Employee Directory
Biotechnology ResearchTexas, United States11-50 Employees
Cellenkos, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf regulatory T cell (Treg) therapies aimed at reducing inflammation and delivering durable immune modulation for inflammatory and autoimmune diseases. Its CRANE platform enables the selection and enrichment of cord blood-derived Tregs tailored to specific indications, supporting a pipeline that spans rare autoimmune blood disorders, oncology, neurodegenerative diseases, and inflammatory pulmonary disease. These Treg therapies do not require HLA matching, can be manufactured quickly, and are suitable for outpatient administration. Headquartered in Houston, Texas, the company operates in the biotechnology research sector with a small-to-mid-sized team. It originated from licensing a cord blood Treg therapy platform from MD Anderson Cancer Center, anchoring its scientific foundation.